Fixes Book Closure for Final Dividend & AGM
Bliss GVS Pharma Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 08, 2016 to September 14, 2016 (both days inclusive) for the purpose of Payment of Final Dividend & 31st Annual General Meeting (AGM) of the Company to be held on September 14, 2016. Board recommends Final Dividend
Bliss GVS Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 24, 2016 at 3.30 p.m. inter alia, has considered and approved the following:1. Declared Final dividend at the rate of 50% i.e. Re. 0.50 per share.2. Pursuant to section 188 of the Companies Act, 2013 approved the appointment of Mr. Vishal Rao and the reappointment of Mr. Gagan Sharma and Mr. Arjun Ashra in the managerial capacity.... Standalone & Consolidated Financial Results, Form A, Auditors Report for March 31, 2016
Bliss GVS Pharma Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Consolidated Financial Results for the period ended March 31, 20163. Standalone Form A for the period ended March 31, 20164. Consolidated Form A for the period ended March 31, 20165. Standalone Auditors Report for the period ended March 31, 20166. Consolidated Auditors Report for the period ended March 31, 2016 Board to consider Dividend
Bliss GVS Pharma Ltd has informed BSE that the Board Meeting of the Company is scheduled to be held on May 24, 2016 , inter alia, to consider, the Audited Financial Results of the Company for the quarter and year ended March 31, 2016 and dividend if any.Further, pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 read with the provision of the code of fair disclosure of the Company, the... Shareholding for the Period Ended March 31, 2016
Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Bliss GVS Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Outcome of Board Meeting
Bliss GVS Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 11, 2016, has considered & approved the following:1. a. Mr. S.N. Kamaths tenure as Managing Director is extended by 3 years starting from April 01, 2016 and annual salary of Rs. 1.5cr- 1.75cr - 2cr.b. Dr. Vibha Gagan Sharmas tenure as Wholetime Director is extended by 3 years starting from January 27, 2016 and annual salary of Rs. 35 lakh - 40 lakh - 45 lakh.... Financial Results, Limited Review Report for December 31, 2015
Bliss GVS Pharma Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20152. Standalone Limited Review for the period ended December 31, 2015 Board Intimation for Results & Closure of Trading Window
Bliss GVS Pharma Ltd has informed BSE that the Board Meeting of the Company is scheduled to be held on February 11, 2016, inter alia, to consider the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2015.Further, Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 read with the provision of the code of fair disclosure of the Company, the trading...